ADC Therapeutics reported a notable increase in net product revenue for ZYNLONTA, reaching $22.3 million in Q4 2025, up from $16.4 million the previous year. This growth is attributed to variability in customer ordering patterns and the activation of new accounts. For the full year, the company maintained a stable revenue of $73.6 million in the third-line plus DLBCL indication, while also achieving a significant reduction in operating expenses, down approximately 50% due to strategic restructuring.
The financial performance reflects a positive trend, with net losses narrowing to $6.4 million for the quarter and $142.6 million for the year, improved from the previous year’s figures. ADC Therapeutics anticipates further growth opportunities with the upcoming LOTIS-5 data release in Q2 2026, which could expand ZYNLONTA’s market share in earlier treatment lines. Management projects potential peak U.S. revenues for ZYNLONTA between $600 million and $1 billion, contingent on regulatory approvals and compendia inclusion.
Investors should note the strategic positioning of ZYNLONTA in a competitive market, with upcoming clinical data expected to drive interest and potentially enhance revenue projections. The company’s solid cash position of $261 million ensures a runway for continued development and operational flexibility through at least 2028.
Source: fool.com